Association of Urinary N7-(1-hydroxyl-3-buten-1-yl) Guanine (EB-GII) Adducts and Butadiene-Mercapturic Acids with Lung Cancer Development in Cigarette Smokers
View abstract on PubMed
Summary
This summary is machine-generated.Urinary biomarkers monohydroxybutenyl mercapturic acid (MHBMA), dihydroxybutyl mercapturic acid (DHBMA), and N7-(1-hydroxyl-3-buten-1-yl) guanine (EB-GII) are elevated in smokers who develop lung cancer. These markers correlate with 1,3-butadiene exposure and lung cancer risk.
Area Of Science
- Environmental Health
- Toxicology
- Cancer Epidemiology
Background
- 1,3-Butadiene (BD) is a prevalent carcinogen in tobacco smoke.
- Identifying individuals susceptible to smoking-induced lung cancer requires predictive biomarkers.
- Metabolic activation of BD yields reactive intermediates that can form DNA adducts and be detoxified.
Purpose Of The Study
- To quantify urinary biomarkers of 1,3-butadiene exposure in smokers with and without lung cancer.
- To assess the association between these biomarkers and lung cancer risk.
- To investigate potential differences in biomarker levels and risk by race/ethnicity.
Main Methods
- Utilized isotope dilution LC/ESI-HRMS/MS to measure MHBMA, DHBMA, and EB-GII in urine.
- Analyzed samples from 260 smokers who developed lung cancer and 259 matched smoking controls from the Southern Community Cohort.
- Adjusted for age, sex, and race/ethnicity in statistical analyses.
Main Results
- Concentrations of MHBMA, DHBMA, and EB-GII were significantly higher in lung cancer cases versus controls (p < 0.0001 for EB-GII and MHBMA, p = 0.0007 for DHBMA).
- Odds ratios for lung cancer were 1.63 for MHBMA, 1.37 for DHBMA, and 1.97 for EB-GII.
- Associations remained significant after adjusting for smoking dose (total nicotine equivalents).
Conclusions
- Urinary MHBMA, DHBMA, and EB-GII are reliable indicators of 1,3-butadiene exposure from smoking.
- These biomarkers are significantly associated with lung cancer risk in smokers.
- Findings highlight the role of BD exposure in smoking-related lung cancer development.

